Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 20, 2026, 3:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: 0.3% hypromellose Clear all

Conditions: Healthy Volunteers
Interventions: CC-220; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: COVID-19
Interventions: Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 867 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more

Conditions: Conjunctivitis, Allergic
Interventions: Alcaftadine 0.25%, Olopatadine 0.2%, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 10 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Keratoconjunctivitis Due to Adenovirus, Viral Shedding
Interventions: Zirgan, genteal gel; Drug
Lead sponsor: Lifelong Vision Foundation; Other
Eligibility: 14 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: Conjunctivitis, Allergic
Interventions: alcaftadine 0.25% ophthalmic solution, olopatadine 0.2% ophthalmic solution, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 10 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Herpes Zoster Keratitis
Interventions: gancyclovir gel, Hypromellose gel; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 95 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Allergic Conjunctivitis
Interventions: Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol), Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II); Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Autonomic Nervous System Diseases, Orthostatic Hypotension, Dopamine Beta-Hydroxylase Deficiency, Orthostatic Intolerance
Interventions: Standing or upright tilt, Microneurography, QSweat, neck cuff stimulation, phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine, clonidine,yohimbine,metoclopramide,alpha-methyldopa, BodPod, Eye exam, Sleep study, Pain response testing, Metabolic chamber, Brain function studies, Bicycle Exercise Test; Procedure · Device · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 12 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Corneal Epithelium Defect
Interventions: 0.3% hypromellose; Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions: nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX), Theratears tear drop, (Akron, Ann 111 Arbor, MI), patching; Drug · Other
Lead sponsor: The New York Eye & Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Ocular Hypertension
Interventions: bimatoprost 0.01%, travoprost 0.004%, timolol 0.5%, hypromellose 0.3%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Racine, Wisconsin

Conditions: Low Testosterone
Interventions: TAK-448, TAK-448 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 60 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dry Eye Syndromes
Interventions: Carboxymethylcellulose (CMC) Artificial Tears, Preservative-free, CMC-free Artificial Tears (control); Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Keratoconjunctivitis Sicca
Interventions: glycerin, polyethylene glycol 400/propylene glycol; Drug
Lead sponsor: Calm Water Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Strabismus
Interventions: subtenons anesthetic - preservative-free bupivacaine 0.75%, topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel, topical control - 0.5 cc of Hypromellose 0.3% gel, subtenons control - 0.5 cc of Normal Saline; Drug
Lead sponsor: Duke University; Other
Eligibility: 1 Year to 7 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis

A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis

Assessment of Alcon's Ocular Image Quantification System

The Pathophysiology of Orthostatic Hypotension

GenTeal in Perioperative Treatment of Laser Assisted in Situ Keratomileusis LASIK Patients

Post Intravitreal Injection Topical NSAID vs. Patching

Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone

Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome

Tear Film Break-up Time After Instillation of Artificial Tears

Postoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery